PRESS RELEASE
November 29, 2019
During November, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to exercising of options issued pursuant to the employee option program 2015/2019 that Saniona decided upon on the Annual General Meeting on 20 May 2015 for certain employees and key consultants in Saniona. As of November 29, 2019, the registered number of shares and votes in Saniona amounts to 28,412,519.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona. Mobile: +45 2210 9957, E-mail: tf@saniona.com
This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8 a.m. CET on November 29, 2019.
About Saniona
Saniona is a research and development company focused on drugs for eating disorders and diseases of the central nervous system. The company has five programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Attachment
